Using the protect bioinformatics technology combined with animal experiments, it is possible to develop more therapeutic vaccines against ALK positive NSCLC, which also needs further exploration for other types of ALK mutant cancers. This evidence concerns the gene ALK and non-small cell lung carcinoma.